Summarizing, here we demonstrate that CD28-superagonist mediated ex vivo expansion of human Treg, which mechanistically depends on differential PI3K and mTOR-signalling, might be a promising new avenue for the expansion of stable polyclonal Treg intended for Treg-based immunotherapy in transplantation and autoimmunity. The gene discussed is MTOR; the disease is Autoimmunity.